Advertisement
GRFS vs PFE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a Buy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GRFS’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- GRFS’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GRFS’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 3 bullish TA indicator(s).
- GRFS’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 3 bullish, 7 bearish.
Price Growth
GRFS (@Pharmaceuticals: Major) experienced а +2.37% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.79% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.28%. For the same industry, the average monthly price growth was -0.62%, and the average quarterly price growth was +13.81%.
Reported Earning Dates
GRFS is expected to report earnings on Nov 06, 2025.
PFE is expected to report earnings on Nov 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-1.28% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GRFS | PFE | GRFS / PFE | |
| Capitalization | 8.67B | 135B | 6% |
| EBITDA | 1.62B | 20.2B | 8% |
| Gain YTD | 35.719 | -5.265 | -678% |
| P/E Ratio | 19.29 | 12.62 | 153% |
| Revenue | 7.45B | 63.8B | 12% |
| Total Cash | 566M | 13.2B | 4% |
| Total Debt | 8.82B | 60.9B | 14% |
GRFS | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 21 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 84 | 62 | |
PRICE GROWTH RATING 1..100 | 47 | 61 | |
P/E GROWTH RATING 1..100 | 90 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as GRFS (21). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.
PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GRFS (100). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.
PFE's SMR Rating (62) in the Pharmaceuticals Major industry is in the same range as GRFS (84). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.
GRFS's Price Growth Rating (47) in the Pharmaceuticals Major industry is in the same range as PFE (61). This means that GRFS’s stock grew similarly to PFE’s over the last 12 months.
GRFS's P/E Growth Rating (90) in the Pharmaceuticals Major industry is in the same range as PFE (98). This means that GRFS’s stock grew similarly to PFE’s over the last 12 months.
| GRFS | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 46% |
| Stochastic ODDS (%) | 1 day ago 67% | 1 day ago 51% |
| Momentum ODDS (%) | 1 day ago 78% | 1 day ago 54% |
| MACD ODDS (%) | 1 day ago 70% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 74% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 72% | 1 day ago 58% |
| Advances ODDS (%) | 1 day ago 72% | 1 day ago 57% |
| Declines ODDS (%) | 9 days ago 75% | 6 days ago 60% |
| BollingerBands ODDS (%) | 6 days ago 79% | 1 day ago 50% |
| Aroon ODDS (%) | 1 day ago 63% | 1 day ago 60% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GSLC | 130.03 | 0.41 | +0.32% |
| Goldman Sachs ActiveBeta® US LgCp Eq ETF | |||
| XPND | 36.20 | 0.10 | +0.29% |
| First Trust Expanded Technology ETF | |||
| HFSI | 35.56 | 0.04 | +0.10% |
| Hartford Strategic Income ETF | |||
| XMAR | 39.24 | 0.03 | +0.08% |
| FT Vest U.S. Eq Enh & ModBufETF-Mar | |||
| BTO | 35.96 | -0.03 | -0.08% |
| John Hancock Financial Opportunities Fund | |||
GRFS and
Correlation & Price change
A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.
| Ticker / NAME | Correlation To GRFS | 1D Price Change % | ||
|---|---|---|---|---|
| GRFS | 100% | +1.12% | ||
| GIKLY - GRFS | 68% Closely correlated | N/A | ||
| GIFOF - GRFS | 37% Loosely correlated | N/A | ||
| GILD - GRFS | 29% Poorly correlated | +0.46% | ||
| BIIB - GRFS | 28% Poorly correlated | +0.84% | ||
| PFE - GRFS | 28% Poorly correlated | +0.38% | ||
More | ||||
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with GSK. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.38% | ||
| GSK - PFE | 58% Loosely correlated | +3.14% | ||
| NVS - PFE | 58% Loosely correlated | +0.36% | ||
| BIIB - PFE | 57% Loosely correlated | +0.84% | ||
| BMY - PFE | 56% Loosely correlated | +0.07% | ||
| ABBV - PFE | 54% Loosely correlated | +1.16% | ||
More | ||||